Estrella Immunopharma (ESLA) Net Equity Issued and Repurchased (2021 - 2026)
Estrella Immunopharma (ESLA) posted quarterly Net Equity Issued and Repurchased of $8.0 million for Q1 2026, up 661.9% quarter-over-quarter from $1.0 million in Q3 2025.
Estrella Immunopharma (ESLA) Net Equity Issued and Repurchased (2021 - 2026) Analysis & Trends
Estrella Immunopharma (ESLA) has reported Net Equity Issued and Repurchased for 3 consecutive years, with $8.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Equity Issued and Repurchased changed N/A year-over-year to $8.0 million; the TTM figure through Mar 2026 stood at $9.0 million (changed N/A YoY), while the FY2025 annual figure was $2.4 million, up 2919.21% from the prior year.
- Net Equity Issued and Repurchased rose to $8.0 million in Q1 2026 per ESLA's latest filing, from $1.0 million in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $8.0 million in Q1 2026 and bottomed at $1.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Estrella Immunopharma | 32.29 Mn | 32.14 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.00 Mn |
| Mar 31, 2026 | 8.00 Mn |
| Sep 30, 2025 | 1.05 Mn |
| Sep 30, 2025 | 1.05 Mn |
| Mar 31, 2021 | 25,000.00 |
| Mar 31, 2021 | 25,000.00 |